WEC
SPRO icon

Winslow Evans & Crocker’s Spero Therapeutics SPRO Stock Holding History

Winslow Evans & Crocker’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$32K Hold
1,640
– – 0.01% 694
2020
Q3 		$18K Hold
1,640
– – ﹤0.01% 644
2020
Q2 		$22K Buy
+1,640
New +$18.4K 0.01% 601

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Winslow Evans & Crocker's SPRO Position: Q4 2020 in Review

Winslow Evans & Crocker held its Spero Therapeutics (SPRO) position steady in Q4 2020 at 1,640 shares worth $32K. The position accounts for 0.01% of the portfolio, ranked #694.

Winslow Evans & Crocker first reported a position in SPRO in Q2 2020 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold SPRO as of Q4 2020.

  • Winslow Evans & Crocker held 1,640 shares of Spero Therapeutics worth $32K as of Q4 2020.
  • Winslow Evans & Crocker left its Spero Therapeutics share count unchanged in Q4 2020.
  • Spero Therapeutics made up 0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #694 holding.
  • Winslow Evans & Crocker first reported a position in Spero Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.